Correvio Pharma
Mr. David Dean is a member of Correvio’s executive team as Chief Business Development Officer and is responsible for overseeing the company’s business development activities. Mr. Dean first joined Correvio as Vice President, Business Development and Investor Relations with over 15 years of capital markets experience as a top ranked industry analyst focused exclusively on the Canadian healthcare sector, most recently as a Director and Research Analyst at one of Canada’s leading independent investment banks. Mr. Dean attained an M.Sc. from the University of Ottawa (Physiology) as well as an MBA (Finance) from Queen’s University. On top of his research analyst registrations in the United States, he was also a registered representative.
This person is not in any offices
Correvio Pharma
Correvio Pharma Corp. operates as a pharmaceutical company. The Company develops and discovers cardiovascular drugs for the treatment of atrial arrhythmia, congestive heart failure, and bacterial skin infections. Correvio Pharma serves patients worldwide.